Venmax Drugs: No deviation in preferential issue fund usage for Q1FY27
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Venmax Drugs confirms no deviation or variation in use of proceeds from its preferential issue for Q1FY27 (ended June 30, 2026). The company raised Rs. 12.69 crores via conversion of 63.44 lakh equity warrants; total planned raise is Rs. 20.05 crores. Of allocations, Rs. 8.37 crores of Rs. 10 crores for working capital and Rs. 0.20 crores of Rs. 10.05 crores for general corporate purposes and business acquisition have been utilised. Audit Committee reviewed on August 7, 2026 and auditors had no comments.
Confirms proper use of raised funds; no red flags. However, only about Rs. 8.57 crores utilised against full Rs. 20.05 crores plan.